Zacks Research Lowers Earnings Estimates for Zimmer Biomet

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Stock analysts at Zacks Research reduced their Q1 2025 earnings per share (EPS) estimates for Zimmer Biomet in a report issued on Thursday, February 27th. Zacks Research analyst R. Department now anticipates that the medical equipment provider will post earnings of $1.80 per share for the quarter, down from their prior forecast of $2.01. The consensus estimate for Zimmer Biomet’s current full-year earnings is $8.22 per share. Zacks Research also issued estimates for Zimmer Biomet’s Q2 2025 earnings at $2.07 EPS, Q3 2025 earnings at $1.96 EPS, Q4 2025 earnings at $2.52 EPS, FY2025 earnings at $8.35 EPS, Q1 2026 earnings at $2.11 EPS, Q2 2026 earnings at $2.25 EPS, Q3 2026 earnings at $2.17 EPS, Q4 2026 earnings at $2.31 EPS, FY2026 earnings at $8.84 EPS and FY2027 earnings at $9.37 EPS.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the prior year, the business posted $2.20 EPS.

A number of other research analysts have also weighed in on the stock. Raymond James cut their target price on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Royal Bank of Canada cut their price objective on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a report on Friday, February 7th. Stifel Nicolaus lifted their price target on Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research report on Thursday, January 23rd. Finally, JMP Securities reissued a “market outperform” rating and issued a $140.00 price objective on shares of Zimmer Biomet in a research report on Friday, February 7th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Zimmer Biomet currently has a consensus rating of “Hold” and a consensus target price of $124.15.

Zimmer Biomet Price Performance

Shares of Zimmer Biomet stock opened at $105.26 on Monday. Zimmer Biomet has a 1-year low of $97.69 and a 1-year high of $133.90. The firm has a fifty day simple moving average of $105.69 and a 200-day simple moving average of $107.32. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $20.95 billion, a price-to-earnings ratio of 23.65, a PEG ratio of 1.95 and a beta of 1.02.

Institutional Investors Weigh In On Zimmer Biomet

Several large investors have recently modified their holdings of the stock. Dodge & Cox boosted its stake in Zimmer Biomet by 12.0% in the 4th quarter. Dodge & Cox now owns 19,118,436 shares of the medical equipment provider’s stock valued at $2,019,480,000 after buying an additional 2,044,645 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Zimmer Biomet by 1.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,760,444 shares of the medical equipment provider’s stock valued at $1,559,147,000 after purchasing an additional 176,337 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Zimmer Biomet by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider’s stock worth $524,942,000 after purchasing an additional 125,852 shares during the last quarter. Van ECK Associates Corp increased its position in shares of Zimmer Biomet by 5.9% during the 4th quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider’s stock worth $417,814,000 after purchasing an additional 218,688 shares in the last quarter. Finally, Franklin Resources Inc. increased its position in shares of Zimmer Biomet by 398.7% during the 4th quarter. Franklin Resources Inc. now owns 3,497,764 shares of the medical equipment provider’s stock worth $369,469,000 after purchasing an additional 2,796,372 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.91%. The ex-dividend date is Monday, March 31st. Zimmer Biomet’s dividend payout ratio is 21.57%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.